Insights on the Antibody Drug Conjugates Global Market to 2030 - Featuring 6 Dimensions Capital, AbbVie and ABL Bio Among Others

Dublin, Oct. 08, 2021 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market by Indication, Linker, Payload, Target Antigens and Geography: Industry Trends and Global Forecasts, 2021-2030" report has been added to *ResearchAndMarkets.com's* offering.

This report features an extensive study of the current and future potential of ADCs being developed for the treatment of various indications. In addition, it features an elaborate discussion on the likely opportunity for the players engaged in this domain, over the next decade.

Over the years, various technological advancements, such as antibody engineering for site-specific conjugation and enhanced pharmacokinetic and pharmacodynamic properties, have paved the way for antibody drug conjugates (ADCs) to be recognized as potent therapies targeting a wide range of indications, including solid tumors and hematological malignancies. ADCs are engineered therapeutics comprised of monoclonal antibodies attached to potent cytotoxic payloads through chemical linkers.

In fact, the FDA has approved 11 ADCs, namely ado-trastuzumab emtansine (Kadcyla), brentuximab vedotin (Adcetris), inotuzumab ozogamicin (Besponsa), gemtuzumab ozogamicin (Mylotarg), moxetumomab pasudotox (Lumoxiti), polatuzumab vedotin-piiq (Polivy), enfortumab vedotin (Padcev), sacituzumab govitecan (Trodelvy), trastuzumab deruxtecan (Enhertu), belantamab mafodotin-blmf (Blenrep), and loncastuximab tesirine-lpyl (ZynlontaT) till date. The success of these therapeutics can be attributed to their high tumor selectivity and cell-killing potential of monoclonal antibodies, while limiting off target toxicities. These advantages have made ADCs a new frontier of chemotherapy, thus, bringing about a paradigm shift in the treatment protocol of different types of cancer.

The growing popularity of ADCs is evident from the number of patents filed / granted for ADCs, which has increased from 1,992 in 2011 to over 22,700 in the first quarter of 2021. With approximately 80 ADCs being investigated in more than 250 clinical trials, the pharmaceutical industry is witnessing a dynamic shift from conventional technologies to newer and more robust approaches for the development of such complex biomolecules. In the past few years, several well-funded start-ups / small companies, offering advanced linker technologies, more potent warheads, and novel conjugation technologies, were established. Moreover, multiple licensing deals were inked in the past few years between various stakeholders, to advance the development of ADCs product pipeline. It is worth noting that companies are also evaluating their proprietary ADCs in combination with other effective therapeutic modalities, such as epigenetic modulator, immune checkpoint inhibitors, and monoclonal antibodies.

ADC-based combination therapies offer multifaceted advantages, such as reduced drug resistance, improved drug efficacy, shrinking tumor metastasis, and increased cancer survival rates. In addition, novel conjugated drug molecules, such as bicycle drug conjugate (Bicycle Therapeutics), extracellular drug conjugate (Centrose), peptide conjugate (Esperance Pharmaceuticals), phospholipid drug conjugate (Cellectar Biosciences), radionucleotide conjugate (Nordic Nanovector), and tunable drug conjugate (BlinkBio) have also been introduced. Driven by the substantial progress in the use of novel ADC-based combination therapies, the associated clinical results, and ongoing technological advancement, coupled to the marketing authorization of multiple ADCs, the ADC therapeutics market is anticipated to grow at a commendable rate in the mid to long-term.

*Amongst other elements, the report includes:*

· A detailed review of the current market landscape of ADCs, providing information on drug developer(s) and technology provider(s), phase of development (marketed, phase III, phase II/III, phase II, phase I/II, phase I, preclinical / discovery stage) of lead candidates, target antigen (CD30, HER2, CD22, CD33, and Others), type of linker used (VC, Sulfo-SPDB, VA, Hydrazone linker, and Others), type of payload / warhead / cytotoxin (MMAE, DM4, Camptothecin, DM1, MMAF, and Others), type of antibody (Anti-HER2, Anti-TROP2, Anti-CD30, Anti-mesothelin, Anti-CD22, and Others), antibody isotype (IgG, IgG1, IgG2, and IgG4), type of therapy (monotherapy and combination therapy), combination drug(s) (if being evaluated as combination therapy), target indication(s) (breast cancer, blood cancer, colorectal cancer, gastric cancer, gynecological cancer, head and neck cancer, lung cancer, and others), line of treatment (1st line, 2nd line, 3rd line, and Others), route of administration (intravenous and subcutaneous), and dosing frequency (Q1 weeks, Q2 weeks, Q3 weeks, Q4 weeks, and Others).
· Elaborate profiles of companies (shortlisted based on phase of development of the lead drug) and their respective product portfolios. Each profile features a brief overview of the company, its financial information (if available), product portfolio, recent developments, and an informed future outlook.
· An analysis of the most commonly targeted therapeutic indications and details of ADC candidates being developed against them, highlighting key epidemiological facts about the diseases and currently available treatment options, other than ADCs.
· A list of key opinion leaders (KOLs) within this domain, featuring detailed 22 matrices to assess the relative experience of the individuals, who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field. It also includes a schematic world map representation, highlighting the geographical locations of eminent scientists / researchers engaged in this domain. In addition, it presents an analysis assessing the credibility and (relative) level of expertise of different KOLs, based on number of publications, number of citations, number of clinical trials, number of affiliations, and strength of professional network (based on information available on LinkedIn).
· An insightful competitiveness analysis of biological targets, featuring a [A] three-dimensional bubble representation that highlights the targets that are being evaluated for ADC development, taking into consideration the number of lead molecules based on a particular target, phase of development of candidate therapies, number of clinical trials and number of target disease indications, and [B] a five-dimensional spider-web analysis, highlighting the most popular biological targets based on a number of relevant parameters, including affiliated publications, grants received to support research on a particular target, number of industry players involved in drug development efforts based on a singular target and geographical distribution of associated clinical trials.
· An analysis of the recent collaborations (since 2014) focused on the development of ADCs. It includes partnerships inked by various stakeholders in this domain, covering R&D collaborations, licensing agreements (specific to technology platforms and product candidates), product development and commercialization agreements, clinical trial agreements, mergers and acquisitions, and other relevant agreements.
· An analysis of the investments made, including seed funding, venture capital financing, debt funding, grants, capital raised from IPOs and subsequent offerings, at various stages of development, in companies that are focused on developing ADCs.
· An in-depth analysis of the various patents that have been filed / granted related to ADCs. It includes information on key parameters, such as patent type, publication year, geographical location, issuing authority, assigned CPC symbol, emerging focus areas, and leading industry / academic players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.
· A study of the various grants that have been awarded to research institutes engaged in projects related to ADCs, between 2016 and 2021, highlighting various important parameters, such as year of award, support period, amount awarded, funding institute, grant type, focus area, type of recipient organization, key project leaders, key regions, and leading recipient organizations.
· An in-depth analysis of completed, ongoing, and planned clinical studies of various ADCs, based on several relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), study focus, target disease indication, and key geographical regions.
· An elaborate discussion on the various strategies that can be adopted by the drug developers across key commercialization stages, namely prior to product launch, during / post launch, including a timeline representation of the key strategies adopted by drug developers for the commercialization of their proprietary products.

*Key Questions Answered*

· Who are the leading players engaged in the development of ADCs?
· Which indications can be treated with ADCs?
· Which partnership models are commonly adopted by stakeholders in this domain?
· What are the investment trends in this industry?
· Which are the most active clinical trial centers?
· Who are the key opinion leaders that can help you drive your development efforts?
· How is the current and future market opportunity likely to be distributed across key market segments?

*Key Topics Covered:*

*1. PREFACE*

*2. EXECUTIVE SUMMARY*

*3. INTRODUCTION*

*4. MARKET OVERVIEW*

*5. COMPANY AND DRUG PROFILES*

*6. KEY THERAPEUTIC AREAS*

*7. KEY OPINION LEADERS*

*8. TARGET COMPETITIVENESS ANALYSIS*

*9. PARTNERSHIPS AND COLLABORATIONS*

*10. FUNDING AND INVESTMENT ANALYSIS*

*11. PATENT ANALYSIS*

*12. ACADEMIC GRANTS*

*13. CLINICAL TRIAL ANALYSIS*

*14. KEY COMMMERCIALIZATION STRATEGIES*

*15. PROMOTIONAL ANALYSIS*

*16. COMBINATION THERAPIES*

*17. NOVEL CONJUGATION TECHNOLOGY PLATFORMS*

*18. ASSESMENT OF NON-CLINICAL DATA, FIRST IN HUMAN DOSING*

*19. COST PRICE ANALYSIS*

*20. CASE STUDY: CONTRACT MANUFACTURING OF ADCs*

*21. CASE STUDY: COMPANION DIAGNOSTICS FOR ADC THERAPEUTICS*

*22. SWOT ANALYSIS*

*23. MARKET FORECAST AND OPPORTUNITY ANALYSIS*

*24. EXECUTIVE INSIGHTS*

*25. CONCLUSION*

*26. APPENDIX 1: TABULATED DATA*

*27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS*

*Companies Mentioned*

· 3SBio
· 3W Partners
· 4BIO Capital
· 5AM Ventures
· 6 Dimensions Capital
· AbbVie
· ABL Bio
· AbTis
· Actinium Pharmaceuticals (ATNM)
· Acuta Capital Partners
· Adage Capital Management
· Adagene
· ADC Therapeutics
· Adcendo
· Advanced Proteome Therapeutics
· Advantech
· Agensys
· Ajinomoto Bio-Pharma
· Ally Bridge Group
· Alphamab Oncology
· Alta Partners
· Alteogen
· AltruBio
· Ambrx
· Amgen
· Amgen Ventures
· Angiex
· Antikor Biopharma
· Apricot Capital
· Aravis
· ARCH Venture Partners
· Arix Bioscience
· Arrowpoint Partners
· Asana BioSciences
· Astellas Pharma
· AstraZeneca
· Auven Therapeutics
· Avacta
· Avalon Ventures
· AVICT Global
· Avipep Therapeutics
· AVROBIO
· Bayer
· Bayern Kapital
· BDC Capital
· Beam Therapeutics
· BeiGene
· BioAtla
· BioGeneration Ventures (BGV)
· BioMed Valley Discoveries
· BioMedPartners
· Biotest
· BlackRock
· BlinkBio
· Boehringer Ingelheim
· Boehringer Ingelheim Venture Fund
· BOM Capital
· Boxer Capital
· Boyu Capital
· Bregua
· BrickBio
· BrightGene Bio-Medical Technology
· Bristol-Myers Squibb
· btov Partners
· BVF Partners
· Byondis
· Calculus Capital
· California Institute for Regenerative Medicine (CIRM)
· Cambridge Enterprise, University of Cambridge
· Canaan Partners
· Cancer Prevention and Research Institute of Texas (CPRIT)
· Cancer Research Technology (CRT)
· Cancer Research UK
· Casdin Capital
· Catalent
· Catalent Biologics
· CEL Healthcare
· Celgene
· Cellerant Therapeutics
· Celltrion
· Centre for the Commercialization of Antibodies and Biologics (CCAB)
· Centrose
· Changjinboya
· Chengcheng Capital
· Chiesi Ventures
· Children's Hospital Los Angeles
· China Life Private Equity Investment
· China Venture Capital Fund (CVC)
· CITIC Private Equity (CPE)
· Clovis Oncology
· Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)
· Coparion
· Cormorant Asset Management
· Crescendo Biologics
· CStone Pharmaceuticals
· CTI Life Sciences Fund
· CureMeta
· CytomX Therapeutics
· Daiichi Sankyo
· Debiopharm
· Decheng Capital
· Deerfield Management
· Diatheva
· dievini Hopp BioTech
· Efung Capital
· EirGenix
· Eli Lilly
· EMD Serono
· Esperance Pharmaceuticals
· Essex Bio-Technology
· Eurostars
· Eventide
· Everest Medicines
· Exelixis
· Farallon Capital
· Femtogenix
· Fidelity Investments
· Five Prime Therapeutics
· Florida Institute of Technology
· Fonds de solidarite FTQ
· Foresite Capital
· Fortis Therapeutics
· Fosun Pharma (formerly Shanghai Fosun Pharmaceutical)
· Freenome
· GamaMabs Pharma
· Genentech
· GeneQuantum Healthcare
· General Insurance Corporation of India (GIC)
· Genmab
· Genor Biopharma
· GIC
· Gilde Healthcare
· Gilead Sciences
· GlaxoSmithKline
· Global Bio-India
· Glycotope
· Glykos
· Glythera
· Goodwin Biotechnology
· Greater Bay Area Fund
· GT Biopharma
· Guotai Venture Capital
· Gustave Roussy
· Hangzhou DAC Biotech
· Harbour BioMed
· HBM Healthcare Investments
· HealthCap
· Heidelberg Pharma
· Hercules Capital
· Heritage Provider Network
· High-Tech Grunderfonds
· Hillhouse Capital
· Hisun Pharmaceuticals
· Hofon Capital
· Sichuan Hongbo Equity Investment Fund Management
· HOPU Investments
· Huadong Medicine
· Huagai Capital
· Hudson Bay Capital Management
· Humanwell Healthcare
· Iconic Therapeutics
· Iksuda Therapeutics
· ImmuneOncia Therapeutics
· ImmunoBiochem
· ImmunoGen
· Immunome
· Immunomedics (acquired by Gilead Sciences)
· Innate Pharma
· Innovate UK
· Invenra
· Invus
· IONTAS
· IP Group
· iProgen Biotech
· Janchor Partners
· Janus Henderson Investors
· Jazz Pharmaceuticals
· Jiangsu Hengrui Pharmaceuticals
· JLABS
· Johnson & Johnson Innovation
· Johnson Matthey
· JT New Century
· JX Partners
· K2 Investment
· Kairos Therapeutics
· King Star Capital
· Kite Pharma
· KLUS Pharma
· Lake Bleu Capital
· Laurion Capital Management
· Legend Capital
· LegoChem Biosciences
· Levena Biopharma
· LifeSci Venture Partners
· Lilly Asia Ventures (LAV)
· Lilly Ventures
· Logos Capital
· Loyal Valley Capital
· Lumira Capital
· MAB Discovery
· MabSpace Biosciences
· MabVax
· MacroGenics
· Magenta Therapeutics
· Matrix Capital Management
· Mayo Clinic
· MediaPharma
· MedImmune (acquired by AstraZeneca)
· Meltwind
· Memorial Sloan Kettering Cancer Center
· Menarini
· Merck
· Merck KGaA
· Mersana Therapeutics
· Millennium Pharmaceuticals
· MilliporeSigma
· Minomic
· Shanghai Miracogen
· Mitsubishi Tanabe Pharma
· Morphotek (Eisai)
· MS Ventures
· Multiple Myeloma Research Foundation (MMRF)
· Myeloma Investment Fund
· NanoValent Pharmaceuticals
· National Cancer Institute (NCI)
· National Research Council of Canada (NRC)
· Navrogen
· NBE-Therapeutics
· Nerviano Medical Sciences
· New Enterprise Associates
· Nexthera Capital
· Nordic Nanovector
· Northeast Securities Prosperity Healthcare Fund
· NovImmune
· Novo Holdings
· NovoCodex Biopharmaceuticals
· o2h Ventures
· OBI Pharma
· OCCIDENT
· OGD2 Pharma
· Oncolinx
· Oncomatryx Biopharma
· OPKO Health
· OrbiMed Advisors
· Oriza Seed Venture Capital
· Osage University Partners
· Otsuka Pharmaceutical
· Overland ADCT BioPharma
· Oxford BioTherapeutics (OBT)
· Oxford Finance
· PAG
· Pappas Capital
· Perceptive Advisors
· Pfizer
· Pfizer Ventures
· pH Pharma
· PharmAbcine
· PharmaMar
· Philogen
· PICC Capital Equity Investment
· Pierre Fabre
· PolyTherics
· PPF Capital Partners Fund
· Puma Biotechnology
· Pureos Bioventures
· Pyxis
· Pyxis Oncology
· Qiming Venture Partners
· Quantum Leap
· RA Capital Management
· Rakuten
· Rakuten Medical
· Ramot
· Recepta Biopharma
· Redalpine
· Redmile Group
· Redwood BioScience
· Regeneron Pharmaceuticals
· RemeGen
· The Research Council of Norway
· Ridgeback Capital Investments
· Roche
· Roche Venture Fund
· Rock Springs Capital
· RTW Investments
· Samsara BioCapital
· Samsung Biologics
· Sanofi
· Sarah Cannon Research Institute
· SBI Group
· Schroder Adveq (acquired by Schroders)
· Seagen
· Sequoia Capital China
· Seventure Partners
· Shanghai Pharmaceuticals
· Shengda Group
· Shenogen Pharma
· Siamab Therapeutics
· Silicon Valley Bank
· Sinopharm Capital
· SK
· Skyline Ventures
· Sofinnova Ventures
· Soleus Capital
· SOPHiA GENETICS
· Sorrento Therapeutics
· SOTIO
· Springworks
· Starling Ventures
· Start Codon
· Stonebridge Capital
· Surveyor Capital
· Sutro Biopharma
· Suvretta Capital Management
· Suzhou Wuzhong Biomedicine Industrial Park Investment
· SV Health Investors
· Synaffix
· SyndicateRoom
· Syndivia
· Synthon
· T. Rowe Price Associates
· Taikang Insurance Group
· Takeda Oncology
· Takeda Pharmaceutical
· Takeda Ventures
· Tekla Capital Management
· Terra Magnum Capital Partners (TMCP)
· TF Capital
· The Column Group
· The Scripps Research Institute
· Third Rock Ventures
· TOT BIOPHARM
· TRIO Pharmaceuticals
· Triphase Accelerator
· TRITON FUNDS
· Tubulis
· UCB
· University of Copenhagen
· University of Wisconsin Carbone Cancer Center (UWCCC)
· Vaccinex
· VelosBio (acquired by Merck)
· Venrock Healthcare Capital Partners
· Vertex Ventures
· VI Partners
· Vida Ventures
· Viking Global Investors
· Vir Biotechnology
· Visterra
· Vivo Capital
· Wellington Management
· WILD Family Office
· Wild Ventures
· WS Investments
· WuXi AppTec (formerly known as WuXi PharmaTech)
· WuXi Biologics
· WuXi Healthcare Ventures
· WuXi STA
· Xintela
· Y-Biologics
· York University
· Ysios Capital
· Yuanda China
· Yuhan Corporation
· Yunfeng Capital
· Zhejiang Teruisi Pharmaceutical
· Zhejiang University Future Capital
· Zheshang Venture Capital
· Zymeworks

For more information about this report visit https://www.researchandmarkets.com/r/lsyl57

CONTACT: CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900